← Eichor
Condition: Apl Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Apl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
Phase 4 · 10 location(s) · Peking University First Hospital · NCT06722586Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Phase 2 · 31 location(s) · Associazione Italiana Ematologia Oncologia Pediatrica · NCT04793919Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acut
Phase 2 · 5 location(s) · M.D. Anderson Cancer Center · NCT01409161PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed A
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT02390635Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
Phase N/A · 1 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT07080970Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Phase 2 · 5 location(s) · Shanghai Jiao Tong University School of Medicine · NCT05881265Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearan
NA · 1 location(s) · Affiliated Hospital of Nantong University · NCT06643962A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and
Phase 2 · 78 location(s) · Apellis Pharmaceuticals, Inc. · NCT07215390Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Phase 3 · 12 location(s) · Quetzal Therapeutics · NCT07504458Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Prom
Phase 3 · 1 location(s) · First Affiliated Hospital Xi'an Jiaotong University · NCT07503730Frontline Oral Arsenic Trioxide for APL
Phase 2 · 2 location(s) · The University of Hong Kong · NCT04687176RWE of 1st Line Treatment With ATO/ATRA for Adult APL
Phase N/A · 6 location(s) · Grupo Argentino de Tratamiento de la Leucemia Aguda · NCT04897490Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
Phase 2 · 1 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06982274
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.